Provided by Tiger Trade Technology Pte. Ltd.

Longeveron Inc

2.69
-0.0300-1.10%
Pre-market: 2.730.0368+1.37%07:13 EDT
Volume:54.97K
Turnover:146.90K
Market Cap:8.50M
PE:-0.27
High:2.80
Open:2.73
Low:2.61
Close:2.72
52wk High:12.30
52wk Low:2.30
Shares:3.16M
Float Shares:2.73M
Volume Ratio:0.62
T/O Rate:2.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-10.0000
EPS(LYR):-12.9172
ROE:-203.61%
ROA:-90.95%
PB:0.82
PE(LYR):-0.21

Loading ...

Longeveron Says Phase 2b Trial Shows Laromestrocel Improves Physical Condition in Age-Related Frailty Patients

Reuters
·
16 hours ago

Longeveron to Participate in Three Longevity/Aging Investment Conferences

GlobeNewswire
·
16 hours ago

Longeveron Says ELPIS II Phase 2b Trial of Laromestrocel in HLHS Misses Primary Endpoint at 12 Months

Reuters
·
Sep 24

Analysts Offer Insights on Healthcare Companies: Bausch + Lomb Corporation (BLCO) and Longeveron (LGVN)

TIPRANKS
·
Sep 21

Top Midday Decliners

MT Newswires Live
·
Sep 18

Longeveron Stock (LGVN) Plummets 56% on a Failed Clinical Trial

TIPRANKS
·
Sep 18

Stocks to Watch: Generac, Vicor, Longeveron, Viant

Dow Jones
·
Sep 17

Longeveron Explores Strategic Options After Therapy Fails Mid-Stage Trial for Infant Heart Condition

Reuters
·
Sep 17

Longeveron Exploring Options to Maximize Shareholder Value After Heart Disease Drug Misses Endpoint

Dow Jones
·
Sep 17

Longeveron Says ELPIS II Trial of Laromestrocel in Hypoplastic Left Heart Syndrome Misses Primary Endpoint

Reuters
·
Sep 17

Longeveron to resume trading at 5:55 pm ET

TIPRANKS
·
Sep 17

Longeveron’s laromestrocel did not meet primary endpoint in Phase 2b HLHS trial

TIPRANKS
·
Sep 17

Longeveron exploring all options for maximizing shareholder value

TIPRANKS
·
Sep 17

Longeveron Announces Topline Results from Elpis Ii Phase 2B Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (Hlhs)

THOMSON REUTERS
·
Sep 17

Longeveron - no Deaths in Laromestrocel-Treated Patients over 12 Months

THOMSON REUTERS
·
Sep 17

Longeveron - Company Initiates Process to Optimize Cost Containment and Maximize Shareholder Value

THOMSON REUTERS
·
Sep 17

Longeveron: Intends to Pursue Funding Sources & Other Potential Revenue Opportunities to Advance Laromestrocel in Longevity & Aging-Related Frailty

THOMSON REUTERS
·
Sep 17

Longeveron Inc: Initiated a Process to Review All Options

THOMSON REUTERS
·
Sep 17

Longeveron - Elpis Ii Trial Did not Meet Primary Endpoint of Rvef Improvement at Month 12

THOMSON REUTERS
·
Sep 17

Longeveron Inc trading halted, news pending

TIPRANKS
·
Sep 17